MaxCyte has signed another multi-product clinical and commercial licence agreement, this time with Vor Biopharma after signing a similar deal with Editas last month. This licence agreement will allow Vor Biopharma to use MaxCyte’s ExPERT flow electroporation instruments to develop and commercialise up to five oncology therapies. The lead therapy is VOR33, and uses engineered haemopoietic stem cells to allow acute myeloid lymphoma (AML) patients to be better treated. The strength of MaxCyte’s technology in enabling novel cell therapies to be developed is also highlighted by the initial data from Vertex/CRISPR Therapeutics with CTX001 in the treatment of beta-thalassaemia and sickle cell disease. We continue to value MaxCyte at £195m (341p/share), but there is now more upside potential.
21 Nov 2019
And yet another commercial licence agreement
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
And yet another commercial licence agreement
MaxCyte, Inc. (MXCT:LON) | 313 0 0.0% | Mkt Cap: 325.9m
- Published:
21 Nov 2019 -
Author:
Mick Cooper PhD -
Pages:
3
MaxCyte has signed another multi-product clinical and commercial licence agreement, this time with Vor Biopharma after signing a similar deal with Editas last month. This licence agreement will allow Vor Biopharma to use MaxCyte’s ExPERT flow electroporation instruments to develop and commercialise up to five oncology therapies. The lead therapy is VOR33, and uses engineered haemopoietic stem cells to allow acute myeloid lymphoma (AML) patients to be better treated. The strength of MaxCyte’s technology in enabling novel cell therapies to be developed is also highlighted by the initial data from Vertex/CRISPR Therapeutics with CTX001 in the treatment of beta-thalassaemia and sickle cell disease. We continue to value MaxCyte at £195m (341p/share), but there is now more upside potential.